Porcine Renin (Sus scrofa domesticus)

Porcine renin is a serine protease aspartyl enzyme derived from pig kidneys that catalyzes the conversion of angiotensinogen to angiotensin I, the rate-limiting step of the renin-angiotensin-aldosterone system (RAAS). No human clinical evidence supports its use as a dietary supplement, and species-specific substrate incompatibility significantly limits its physiological relevance in humans.

Origin & History

Porcine renin is an enzyme derived from the kidneys of domestic pigs (Sus scrofa domesticus), specifically extracted from renal tissue where it exists in active, inactive, and protein-bound forms. It belongs to the aspartyl protease class and is typically purified from porcine renal arteries or kidneys through specialized extraction methods.

Historical & Cultural Context

No evidence of traditional medicinal use exists for porcine renin in any historical systems including Ayurveda, TCM, or folk medicine. It is a modern biochemical isolate primarily studied in research laboratories since the 1970s for understanding RAAS physiology.

Health Benefits

• No established health benefits in humans - no clinical trials exist evaluating porcine renin as a supplement
• May theoretically influence blood pressure regulation through RAAS activation (animal models only)
• Shows species-specific limitations - poor interaction with human angiotensinogen in xenotransplant studies
• Preclinical rat models used 4-20 mU/kg/hour infusions to study hypertension mechanisms (not therapeutic)
• Currently studied only in research contexts, not as a therapeutic agent

How It Works

Porcine renin (EC 3.4.23.15) functions as an aspartyl protease that cleaves the Leu10-Val11 peptide bond of angiotensinogen, releasing the decapeptide angiotensin I. In its native porcine host, this initiates a cascade where angiotensin-converting enzyme (ACE) further processes angiotensin I into the vasoactive angiotensin II, which binds AT1 and AT2 receptors to regulate sodium retention, aldosterone secretion, and vascular tone. However, porcine renin exhibits substantially reduced affinity for human angiotensinogen compared to homologous human renin, due to structural differences in the substrate-binding cleft, rendering this cascade largely inactive when porcine renin is introduced into a human physiological environment.

Scientific Research

No human clinical trials, RCTs, or meta-analyses exist evaluating porcine renin as a supplement. Available data are limited to preclinical animal models (PMIDs: 758231, 2677138) and xenotransplantation contexts, where porcine renin showed poor interaction with human angiotensinogen, leading to hypotension and graft dysfunction (PMID: 36695679).

Clinical Summary

No published randomized controlled trials, cohort studies, or any human clinical data exist evaluating porcine renin as an oral or supplemental intervention in humans. The foundational research on porcine renin derives from biochemical characterization studies conducted in the 1970s and 1980s, which were primarily used as research tools to understand RAAS pharmacology rather than as therapeutic agents. Animal model studies in rodents and pigs have demonstrated renin's role in blood pressure elevation and fluid homeostasis, but these findings cannot be extrapolated to human supplementation due to species-specific enzymatic incompatibilities. The overall evidence base for porcine renin as a supplement is effectively nonexistent, placing it in the lowest tier of evidence for any claimed human health benefit.

Nutritional Profile

Porcine renin is a purified proteolytic enzyme protein (aspartyl protease class) with negligible direct nutritional value as consumed in trace quantities. Molecular weight approximately 37-40 kDa as a glycoprotein. Protein content constitutes ~95-98% of dry mass when in purified form, though administered doses are measured in milli-units (mU), not grams, rendering macronutrient contribution effectively zero (<0.001g protein per therapeutic dose). Contains no meaningful carbohydrate, fat, or fiber content in isolated form. Glycosylation sites carry N-linked oligosaccharide chains (~8-10% of molecular weight by mass) composed of mannose and N-acetylglucosamine residues. As an enzyme derived from porcine renal juxtaglomerular cells, it contains trace zinc and calcium ions as cofactors stabilizing tertiary structure, estimated at <1 µg per administered unit dose. Bioavailability as an intact enzyme: essentially 0% via oral route due to gastric acid denaturation and proteolytic degradation in the GI tract — retains biological activity only when delivered parenterally (IV or subcutaneous). No vitamins, dietary minerals, or fiber content applicable. Biologically active concentration in research settings: 4–20 mU/kg/hour (IV infusion in rat models). Specific activity of purified preparations typically reported at 1–5 Goldblatt units/mg protein. Human substrate affinity (angiotensinogen cleavage) is significantly reduced versus porcine substrate due to amino acid sequence divergence at the cleavage site.

Preparation & Dosage

No clinically studied dosages exist for porcine renin in humans. Preclinical rat studies used 4-20 mU/kg/hour IV infusions for research purposes only. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Not applicable - no established supplement use

Safety & Interactions

Because no human trials exist, a formal safety profile for porcine renin supplementation has not been established, and any risk assessment is purely theoretical. Individuals taking antihypertensive medications that target the RAAS — including ACE inhibitors (e.g., lisinopril), angiotensin receptor blockers (ARBs such as losartan), or direct renin inhibitors (e.g., aliskiren) — should exercise extreme caution, as even theoretical RAAS activation could interfere with these drug mechanisms. People with pork or porcine protein allergies face a clear contraindication due to the pig-derived origin of the enzyme. Pregnant individuals should avoid porcine renin entirely given the critical role of RAAS balance in gestational blood pressure regulation and the complete absence of safety data.